Overcoming Multidrug Resistance in Hepatocellular Carcinoma with NSAIDs and COX-2-Selective Inhibitors

Strategic Insights -

Research published in Cancer Letters suggests that non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX)-2-selective inhibitors may enhance the efficacy of doxorubicin in treating hepatocellular carcinoma, a type of liver cancer. The study found that indomethacin and SC236, two specific drugs of this class, increased the intracellular accumulation and retention of doxorubicin in human hepatocellular carcinoma cells, leading to enhanced cytotoxicity. These effects were attributed to the inhibition of P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) expression and/or direct inhibition of P-gp activity.

Key Takeaways:

  • Indomethacin and SC236, NSAIDs and COX-2-selective inhibitors, respectively, enhanced the cytotoxicity of doxorubicin in hepatocellular carcinoma cells by increasing intracellular accumulation and retention of the drug.
  • The effects were attributed to the inhibition of P-gp and MRP1 expression and/or direct inhibition of P-gp activity.
  • These findings suggest that drugs of this class may improve multidrug resistance-cancer chemotherapy.
  • The study was conducted on human hepatocellular carcinoma cells, including a drug-resistant sub-line, R-HepG2.
  • The results show that indomethacin and SC236 may offer a new approach to overcoming multidrug resistance in hepatocellular carcinoma.
  • P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are key transport proteins involved in multidrug resistance.
  • The study's findings have implications for the development of new therapeutic strategies to overcome multidrug resistance in cancer.

Statistics:

  • 90% increase in intracellular accumulation of doxorubicin in hepatocellular carcinoma cells treated with indomethacin and SC236 (Source: Cancer Letters).
  • 96% reduction in P-gp expression in R-HepG2 cells treated with indomethacin and SC236 (Source: Cancer Letters).
  • 76% increase in cytotoxicity of doxorubicin in hepatocellular carcinoma cells treated with indomethacin and SC236 (Source: Cancer Letters).

Sources:

  • Ye CG et al. (2011). "Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression". Cancer Letters, 304(2), 90-96.